Thelansis

Pulmonary Hypertension (PH) Market Outlook Thelansis’s “Pulmonary Hypertension (PH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Hypertension (PH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

  Pulmonary Hypertension (PH) Market Outlook Thelansis’s “Pulmonary Hypertension (PH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Hypertension (PH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Pulmonary Hypertension (PH) Overview Pulmonary hypertension (PH) is elevated lung blood pressure from various causes, distinct from systemic hypertension, affecting the entire body. There are five categorized groups of pulmonary hypertension, each linked to specific causes, necessitating varied treatments. Despite these differences, all forms of pulmonary hypertension pose serious and potentially life-threatening risks. P...

  Pulmonary hypertension (PH) is elevated lung blood pressure from various causes, distinct from systemic hypertension, affecting the entire body. There are five categorized groups of pulmonary hypertension, each linked to specific causes, necessitating varied treatments. Despite these differences, all forms of pulmonary hypertension pose serious and potentially life-threatening risks. Pulmonary hypertension (PH) is characterized as a hemodynamic state rather than a standalone diagnosis, with a resting mean pulmonary artery pressure (PAPm) of ≥ 25 mm Hg. Within this category, pulmonary arterial hypertension represents a specific subgroup defined by unique hemodynamic features. These include precapillary pulmonary hypertension, elevated pulmonary vascular resistance (PVR), PAPm ≥ 25 mm Hg, normal pulmonary arterial wedge pressure (PAWP) ≤ 15 mm Hg, and PVR >240 dyn × s × cm-5 in individuals of any age, be they children or adults. Primary causes of pulmonary hypertension often i...